Literature DB >> 31541986

Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients.

Tushar Issar1, Ria Arnold2, Natalie C G Kwai3, Susan Walker1, Aimy Yan1, Adeniyi A Borire1, Ann M Poynten4, Bruce A Pussell5, Zoltan H Endre5, Matthew C Kiernan6, Arun V Krishnan7.   

Abstract

OBJECTIVE: Chronic kidney disease (CKD) caused by diabetes is known as diabetic kidney disease (DKD). The present study aimed to examine the underlying mechanisms of axonal dysfunction and features of neuropathy in DKD compared to CKD and type 2 diabetes (T2DM) alone.
METHODS: Patients with DKD (n = 30), CKD (n = 28) or T2DM (n = 40) and healthy controls (n = 41) underwent nerve excitability assessments to examine axonal function. Neuropathy was assessed using the Total Neuropathy Score. A validated mathematical model of human axons was utilised to provide an indication of the underlying causes of nerve pathophysiology.
RESULTS: Total neuropathy score was significantly higher in patients with DKD compared to those with either CKD or T2DM (p < 0.05). In DKD, nerve excitability measures (S2 accommodation and superexcitability, p < 0.05) were more severely affected compared to both CKD and T2DM and worsened with increasing serum K+ (p < 0.01). Mathematical modelling indicated the basis for nerve dysfunction in DKD was an elevation of extracellular K+ and reductions in Na+ permeability and the hyperpolarisation-activated cation current, which was similar to CKD.
CONCLUSIONS: Patients with DKD manifested a more severe neuropathy phenotype and shared features of nerve dysfunction to that of CKD. SIGNIFICANCE: The CKD, and not diabetes component, appears to underlie axonal pathophysiology in DKD.
Copyright © 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Diabetic kidney disease; Diabetic nephropathy; Diabetic neuropathy; Nerve excitability; Uremic neuropathy

Mesh:

Year:  2019        PMID: 31541986     DOI: 10.1016/j.clinph.2019.08.005

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  6 in total

Review 1.  Pharmacological Activities of Safflower Yellow and Its Clinical Applications.

Authors:  Yan Chen; Meifeng Li; Jiayu Wen; Xiaoqi Pan; Zixin Deng; Junren Chen; Guanru Chen; Lei Yu; Yunli Tang; Gangmin Li; Xiaofang Xie; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-27       Impact factor: 2.650

Review 2.  Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.

Authors:  Jeremy Chung Bo Chiang; Ria Arnold; Roshan Dhanapalaratnam; Maria Markoulli; Arun V Krishnan
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-15

3.  Association Between Early Markers of Renal Injury and Type 2 Diabetic Peripheral Neuropathy.

Authors:  Zhi Yang; Xiaoyang Lou; Jie Zhang; Ronghui Nie; Jiang Liu; Ping Tu; Peng Duan
Journal:  Diabetes Metab Syndr Obes       Date:  2021-10-30       Impact factor: 3.168

Review 4.  Precision prognostics for the development of complications in diabetes.

Authors:  Catarina Schiborn; Matthias B Schulze
Journal:  Diabetologia       Date:  2022-06-21       Impact factor: 10.460

5.  Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure: A Randomized Controlled Trial.

Authors:  Amy Kang; Ria Arnold; Martin Gallagher; Paul Snelling; Julianne Green; Mangalee Fernando; Matthew C Kiernan; Samantha Hand; Kim Grimley; Jenny Burman; Anne Heath; Kris Rogers; Amritendu Bhattacharya; Brendan Smyth; Thomas Bradbury; Carmel Hawley; Vlado Perkovic; Arun V Krishnan; Meg J Jardine
Journal:  Clin J Am Soc Nephrol       Date:  2021-07-07       Impact factor: 10.614

6.  Peripheral nerve morphology and intraneural blood flow in chronic kidney disease with and without diabetes.

Authors:  Tushar Issar; Susan Walker; Ria Arnold; Ann M Poynten; Zoltan H Endre; Arun V Krishnan
Journal:  Muscle Nerve       Date:  2022-02-23       Impact factor: 3.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.